Cancer remains one of the most dreaded ailments anyone can suffer from. Often, those suffering from the disease don't even realise it till it's too late.

To change this narrative, researchers, as per a report in Science Alert, are working on harnessing the capabilities of engineered bacteria. These bacteria will help scientists and doctors detect early signs of colorectal cancer in the human body.&nbsp;

<h2>How does that work?</h2>

The approach involves using modified microbes as diagnostic tools. Taking advantage of the fact that our gastrointestinal tract is naturally inhabited by various bacteria, scientists have for years been trying to harness the natural abilities of some specific strains, and use them as probiotic sensors. Finally, they might've cracked the code.

Also read |&nbsp;<a href="https://www.wionews.com/science/virgin-galactics-tourist-astronauts-left-starstruck-after-trip-to-edge-of-space-watch-624619">Virgin Galactic's tourist 'astronauts' left 'starstruck' after trip to edge of space. Watch!</a>

In this study, a team of researchers led by biologist Robert Cooper at the University of California, San Diego, used a bacterium called Acinetobacter baylyi. The bacterium is known for its ability to collect DNA from its environment.&nbsp;

They genetically engineered it to target specific DNA sequences associated with colorectal cancer mutations. It was used to detect snippets of DNA shed from lab-grown colorectal cancer cells and mice harbouring colorectal tumours.&nbsp;

<h2>Diagnosing abilities</h2>

As per the&nbsp;study author Susan Woods, "This study demonstrates how bacteria can be designed to detect specific DNA sequences to diagnose disease in hard-to-reach places."&nbsp;

How it works is very fascinating. When the bacterium encountered these cancer-related DNA snippets, it incorporated them into its own genome, which in turn triggered the activation of an antibiotic resistance gene.&nbsp;

Also read |&nbsp;<a href="https://www.wionews.com/science/lakeside-fortresses-and-ancient-stilts-scientists-unearthing-europes-oldest-village-624577">Scientists unearth Europe’s oldest lakeside stilt village behind a fortress of defensive spikes</a>

This allowed the modified bacteria to grow on agar plates containing antibiotics, and provided researchers a clear signal that cancer cells had been detected.

"This shows that our biosensing system can be used to catch colorectal cancer DNA within a complex ecosystem," says biomedical scientist Woods, who is working at the University of Adelaide in Australia.

<h2>The groundbreaking benefits</h2>

As per the report, this detection system's sensitivity&nbsp;and reliability in detecting cancer cells from stool samples will help determine its potential for clinical use.&nbsp;

Early detection of colorectal cancer could significantly improve a patient's survival rate. However, as&nbsp;per the study published in Science, while the research is promising, it still requires further exploration and testing before it could&nbsp;be used in patients.&nbsp;

(With inputs from agencies) 
 
&nbsp;

WATCH WION LIVE HERE

<iframe allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="" frameborder="0" height="350" loading="”lazy”" src="https://www.wionews.com/live-tv/embed?autoplay=1&amp;mute=1" width="100%"></iframe>

You can now write for wionews.com and be a part of the community. Share your stories and opinions with us <a href="https://www.wionews.com/content-contribution-registration-form">here</a>.

Cancer remains one of the most dreaded ailments anyone can suffer from. Often, those suffering from the disease don't even realise it till it's too late. To change this narrative, researchers, as per a report in Science Alert, are working on harnessing the capabilities of engineered bacteria.

Cancer remains one of the most dreaded ailments anyone can suffer from. Often, those suffering from the disease don't even realise it till it's too late. To change this narrative, researchers, as per a report in Science Alert, are working on harnessing the capabilities of engineered bacteria. These bacteria will help scientists and doctors detect early signs of colorectal cancer in the human body. How does that work? The approach involves using modified microbes as diagnostic tools. Taking advantage of the fact that our gastrointestinal tract is naturally inhabited by various bacteria, scientists have for years been trying to harness the natural abilities of some specific strains, and use them as probiotic sensors. Finally, they might've cracked the code. Also read | Virgin Galactic's tourist 'astronauts' left 'starstruck' after trip to edge of space. Watch! In this study, a team of researchers led by biologist Robert Cooper at the University of California, San Diego, used a bacterium called Acinetobacter baylyi. The bacterium is known for its ability to collect DNA from its environment. They genetically engineered it to target specific DNA sequences associated with colorectal cancer mutations. It was used to detect snippets of DNA shed from lab-grown colorectal cancer cells and mice harbouring colorectal tumours. Diagnosing abilities As per the study author Susan Woods, "This study demonstrates how bacteria can be designed to detect specific DNA sequences to diagnose disease in hard-to-reach places." How it works is very fascinating. When the bacterium encountered these cancer-related DNA snippets, it incorporated them into its own genome, which in turn triggered the activation of an antibiotic resistance gene. Also read | Scientists unearth Europe’s oldest lakeside stilt village behind a fortress of defensive spikes This allowed the modified bacteria to grow on agar plates containing antibiotics, and provided researchers a clear signal that cancer cells had been detected. "This shows that our biosensing system can be used to catch colorectal cancer DNA within a complex ecosystem," says biomedical scientist Woods, who is working at the University of Adelaide in Australia. The groundbreaking benefits As per the report, this detection system's sensitivity and reliability in detecting cancer cells from stool samples will help determine its potential for clinical use. Early detection of colorectal cancer could significantly improve a patient's survival rate. However, as per the study published in Science, while the research is promising, it still requires further exploration and testing before it could be used in patients. (With inputs from agencies) WATCH WION LIVE HERE You can now write for wionews.com and be a part of the community. Share your stories and opinions with us here.

Engineered bacteria offer new hope for early detection of cancer

By: Julia von Oettingen and&nbsp;Rajesh Vedanthan*

Prince, a three-year-old boy, is brought to the emergency room in Monrovia, Liberia, with fever and a decreased level of consciousness. He is critically ill. He is treated for malaria.

Time is the only way to tell if this was the right treatment choice — but time may not be on his side. An astute nurse asks a visiting doctor if she can borrow a blood glucose monitor and nails the diagnosis: Type 1 diabetes, requiring urgent administration of insulin to save the boy's life.

While Prince was lucky to get a correct diagnosis on time, blood glucose monitors are rarely available in resource-limited clinics in sub-Saharan Africa.

Situations like this occur daily in low-resource settings: A sick patient, a clinical suspicion, but no confirmatory testing. As a result, many patients are misdiagnosed, receive unnecessary or harmful treatments, or die.

Thankfully, blood glucose measurement — an important laboratory test — just made it onto the first edition of the WHO Essential Diagnostics List (EDL).

This new list is a great step forward in making the most crucial diagnostic tests available globally.

However, future editions of this list will need to cover an even broader range of tests.

Beyond the 'Big Three'

The WHO EDL, published on May 16, 2018, is a first step towards addressing the "diagnostics desert" that health-care providers and patients alike still face in many resource-limited settings.

WHO and its expert committee carefully put together a priority list of essential "in vitro" (laboratory-based) diagnostics to guide governments and health-care stakeholders on what tests to make available. The aim was to address the highest priority health-care needs.

Like its 40-year-old WHO sibling, the Essential Medicines List, this list promises to have a big impact on the availability of laboratory-based diagnostics globally, and on the quality of health-care delivery and population health.

WHO and its expert committee should be applauded for this essential accomplishment, including the effort to look beyond the traditional "Big Three" infections (TB, HIV and malaria).

While the list still has an obvious focus on infectious diseases, the consideration of essential non-communicable diseases (NCD) diagnostics is timely, if not overdue.

Detecting diabetes and heart disease

Cardiovascular disease, chronic respiratory disease, cancer and diabetes have emerged as the most important epidemics of the 21st century.

In an era where such NCDs have surpassed infectious diseases as the major killers globally, it is essential then that international organizations, and specifically the WHO, adapt their policies and guidelines to this reality.

The number of NCD-related diagnostic tests that made it onto the 113-item list establishes an important starting point for the future. For example, making blood glucose measurements a priority will help to improve detection of diabetes among the striking 50 per cent of people in low- and middle-income countries who do not know they have it.

This may give millions the chance of timely treatment and improved long-term outcomes.

A vital blood test for Troponin levels, for example — which helps diagnose a heart attack — can be life-saving. Other laboratory tests (e.g. liver function tests) can help diagnose many NCDs.

An incomplete list

Certainly, this list is not yet complete, but we hope future editions can be. We hope, eventually, to see other essential diagnostics included.

The diagnosis of cancers, such as colon, breast and lung cancers, can be facilitated by tumour markers and pathology diagnostics. Neurologic disorders frequently require cerebrospinal fluid and drug levels. Thyroid function studies help diagnose thyroid dysfunction — one of the most common endocrine disorders.

We also hope to see an eventual expansion of the family of "essentials" to include medical equipment and devices.

These include: Growth charts and blood pressure cuffs at a primary-care level an electrocardiogram, X-ray and ultrasound at a secondary-care level and CT and MRI scanners, lung function tests, surgical devices and fiber-optic scopes at a tertiary-care level.

Affordable and accessible testing

If the EDL is to improve the health of the global population, we will also need to lobby for the five "As" of access: Affordability, availability, accessibility, accommodation and acceptability.

With political guidance, willpower and necessary pressure, public and private entities can work towards affordability of essential diagnostics. We must strengthen national, regional and local health systems — to work out supply chains and laboratory networks that ensure availability and accessibility for a wide public.

We must develop innovative testing strategies that accommodate the needs of remote and vulnerable populations — such as point-of-care tests that can be used by community health workers.

The expansion of the WHO essential list family to include an EDL is a promising start to broadened access to essential diagnostics globally, and to deliver on WHO's goal of Universal Health Coverage.

We need action now — to ensure the list becomes a powerful tool, addressing an ever-broadening spectrum of diseases. This way, every individual can have the chance of a proper diagnosis, treatment and survival.

Julia von Oettingen is an Assistant Professor of Pediatrics, McGill University and Rajesh Vedanthan and Associate Professor in Medicine/Cardiology, Icahn School of Medicine at Mount Sinai.

(Disclaimer: The opinions expressed above are the personal views of the author and do not reflect the views of ZMCL)

(This article was originally published on The Conversation. Read the original <a href="https://theconversation.com/the-desperate-global-need-for-medical-diagnostics-97531">article</a>.)&nbsp;

Cardiovascular disease, chronic respiratory disease, cancer and diabetes have emerged as the most important epidemics of the 21st century

By: Julia von Oettingen and Rajesh Vedanthan* Prince, a three-year-old boy, is brought to the emergency room in Monrovia, Liberia, with fever and a decreased level of consciousness. He is critically ill. He is treated for malaria. Time is the only way to tell if this was the right treatment choice — but time may not be on his side. An astute nurse asks a visiting doctor if she can borrow a blood glucose monitor and nails the diagnosis: Type 1 diabetes, requiring urgent administration of insulin to save the boy's life. While Prince was lucky to get a correct diagnosis on time, blood glucose monitors are rarely available in resource-limited clinics in sub-Saharan Africa. Situations like this occur daily in low-resource settings: A sick patient, a clinical suspicion, but no confirmatory testing. As a result, many patients are misdiagnosed, receive unnecessary or harmful treatments, or die. Thankfully, blood glucose measurement — an important laboratory test — just made it onto the first edition of the WHO Essential Diagnostics List (EDL). This new list is a great step forward in making the most crucial diagnostic tests available globally. However, future editions of this list will need to cover an even broader range of tests. Beyond the 'Big Three' The WHO EDL, published on May 16, 2018, is a first step towards addressing the "diagnostics desert" that health-care providers and patients alike still face in many resource-limited settings. WHO and its expert committee carefully put together a priority list of essential "in vitro" (laboratory-based) diagnostics to guide governments and health-care stakeholders on what tests to make available. The aim was to address the highest priority health-care needs. Like its 40-year-old WHO sibling, the Essential Medicines List, this list promises to have a big impact on the availability of laboratory-based diagnostics globally, and on the quality of health-care delivery and population health. WHO and its expert committee should be applauded for this essential accomplishment, including the effort to look beyond the traditional "Big Three" infections (TB, HIV and malaria). While the list still has an obvious focus on infectious diseases, the consideration of essential non-communicable diseases (NCD) diagnostics is timely, if not overdue. Detecting diabetes and heart disease Cardiovascular disease, chronic respiratory disease, cancer and diabetes have emerged as the most important epidemics of the 21st century. In an era where such NCDs have surpassed infectious diseases as the major killers globally, it is essential then that international organizations, and specifically the WHO, adapt their policies and guidelines to this reality. The number of NCD-related diagnostic tests that made it onto the 113-item list establishes an important starting point for the future. For example, making blood glucose measurements a priority will help to improve detection of diabetes among the striking 50 per cent of people in low- and middle-income countries who do not know they have it. This may give millions the chance of timely treatment and improved long-term outcomes. A vital blood test for Troponin levels, for example — which helps diagnose a heart attack — can be life-saving. Other laboratory tests (e.g. liver function tests) can help diagnose many NCDs. An incomplete list Certainly, this list is not yet complete, but we hope future editions can be. We hope, eventually, to see other essential diagnostics included. The diagnosis of cancers, such as colon, breast and lung cancers, can be facilitated by tumour markers and pathology diagnostics. Neurologic disorders frequently require cerebrospinal fluid and drug levels. Thyroid function studies help diagnose thyroid dysfunction — one of the most common endocrine disorders. We also hope to see an eventual expansion of the family of "essentials" to include medical equipment and devices. These include: Growth charts and blood pressure cuffs at a primary-care level an electrocardiogram, X-ray and ultrasound at a secondary-care level and CT and MRI scanners, lung function tests, surgical devices and fiber-optic scopes at a tertiary-care level. Affordable and accessible testing If the EDL is to improve the health of the global population, we will also need to lobby for the five "As" of access: Affordability, availability, accessibility, accommodation and acceptability. With political guidance, willpower and necessary pressure, public and private entities can work towards affordability of essential diagnostics. We must strengthen national, regional and local health systems — to work out supply chains and laboratory networks that ensure availability and accessibility for a wide public. We must develop innovative testing strategies that accommodate the needs of remote and vulnerable populations — such as point-of-care tests that can be used by community health workers. The expansion of the WHO essential list family to include an EDL is a promising start to broadened access to essential diagnostics globally, and to deliver on WHO's goal of Universal Health Coverage. We need action now — to ensure the list becomes a powerful tool, addressing an ever-broadening spectrum of diseases. This way, every individual can have the chance of a proper diagnosis, treatment and survival. Julia von Oettingen is an Assistant Professor of Pediatrics, McGill University and Rajesh Vedanthan and Associate Professor in Medicine/Cardiology, Icahn School of Medicine at Mount Sinai. (Disclaimer: The opinions expressed above are the personal views of the author and do not reflect the views of ZMCL) (This article was originally published on The Conversation. Read the original article.)

Opinion: The desperate global need for medical diagnostics

diagnostic-tests

Diagnostic Tests, News on Diagnostic Tests, stories on Diagnostic Tests, articles on Diagnostic Tests, Diagnostic Tests stories at Wion, Diagnostic Tests news, Diagnostic Tests latest news